Bionano Genomics Stock
Bionano Genomics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Albert A. Luderer
- Employees
- 96
- Market cap
- $15 M
- IPO
- 21/08/2018
- Web
- bionano.com
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering…
Bionano Genomics stock: price history
1D
-8.8%
1W
-13.2%
1M
-17.2%
6M
-3.1%
YTD
-18.3%
1Y
-37.2%
2Y
-93.7%
5Y
-100.0%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~21% weaker price swings than usual
Ask the agents about Bionano Genomics
Analyst assessment of Bionano Genomics
PRICE TARGET LOW
US$1.00
CONSENSUS
US$46.50
MEDIAN
US$5.00
PRICE TARGET HIGH
US$175.00
0
STRONG BUY
4
BUY
3
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 13/04/2026
Bionano Genomics stock metrics
P/E
-0.34
P/B
0.46
EV/EBITDA
-0.79
RETURN ON EQUITY
-23.5%
NET MARGIN
-90.8%
DEBT/EQUITY
0.21
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.3%
FLOAT SHARES
10,636,398
AVG. DAILY VOLUME (30D)
1,826,835
Insider transactions (SEC)
Luderer Albert
Luderer Albert
OLDAKOWSKI MARK
Chaubey Alka
Dixon Jonathan V.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Bionano Genomics stock
What does Bionano Genomics do?
Bionano Genomics, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Albert A. Luderer, the company employs around 96 people.
The IPO was on 21/08/2018; the stock trades on NASDAQ under the ticker BNGO.
What do analysts say about Bionano Genomics stock?
7 analysts rate the stock, the consensus is Buy (as of 13/04/2026).
The average price target is US$46.50, ranging from US$1.00 to US$175.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Bionano Genomics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -21% stronger than usual.
Does Bionano Genomics pay a dividend?
No, Bionano Genomics currently does not pay a dividend.
Which stocks are comparable to Bionano Genomics?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Bionano Genomics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bionano Genomics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.